In a deal that is an asset disposal in all but name, Basilea Pharmaceutica AG is banking £146 million up front (US$226.8 million) and could get between £30 million and £50 million more in regulatory milestones from a global agreement on its hand eczema drug Toctino (alitretinoin) with Stiefel, the dermatology subsidiary of GlaxoSmithKline plc.
With its diabetes drug lixisenatide already undergoing regulatory review in Europe, Sanofi SA disclosed Monday, during the American Diabetes Association (ADA) meeting in Philadelphia, that it has now filed for regulatory approval in Japan.
In a deal that is an asset disposal in all but name, Basilea Pharmaceutica AG is banking £146 million up front (US$226.8 million) and could get between £30 million and £50 million more in regulatory milestones from a global agreement on its hand eczema drug Toctino (alitretinoin) with Stiefel, the dermatology subsidiary of London-based GlaxoSmithKline plc.
With its diabetes drug lixisenatide already undergoing regulatory review in Europe, Sanofi SA disclosed Monday, during the American Diabetes Association (ADA) meeting in Philadelphia, that it has now filed for regulatory approval in Japan.
Genmab A/S is getting $2 million up front and could receive up to $173 million more in milestone payments on the strength of a deal with Novartis AG on its bispecific antibody technology, DuoBody.
Genzyme Corp.'s once-daily oral multiple sclerosis drug Aubagio (teriflunomide) hit the two main clinical endpoints in a confirmatory pivotal Phase III trial: an annualized reduction in relapse rate and a reduction in the risk of sustained accumulation of disability.
The strategic alliance between BioInvent International AB and ThromboGenics NV received a double whammy, as the two companies halted development of an anticoagulation antibody, TB-402, following unfavorable data from a Phase IIb head-to-head trial against Xarelto (rivaroxaban), while Roche Holding AG decided to exit a three-way alliance to develop an angiogenesis inhibitor, TB-403.
The strategic alliance between BioInvent International AB and ThromboGenics NV received a double whammy, as the two companies halted development of an anticoagulation antibody, TB-402, following unfavorable data from a Phase IIb head-to-head trial against Xarelto (rivaroxaban), while Roche Holding AG decided to exit a three-way alliance to develop an angiogenesis inhibitor, TB-403.
Genzyme Corp.'s once-daily oral multiple sclerosis drug Aubagio (teriflunomide) hit the two main clinical endpoints in a confirmatory pivotal Phase III trial: an annualized reduction in relapse rate and a reduction in the risk of sustained accumulation of disability.
Veloxis Pharmaceuticals A/S is betting the farm on its late-stage organ transplant rejection drug LCP-Tacro and exiting from all other development activities in an effort to stretch out its rapidly dwindling cash resources.
